Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285


Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.

Weeda VB, Murawski M, McCabe AJ, Maibach R, Brugières L, Roebuck D, Fabre M, Zimmermann A, Otte JB, Sullivan M, Perilongo G, Childs M, Brock P, Zsíros J, Plaschkes J, Czauderna P, Aronson DC.

Eur J Cancer. 2013 Aug;49(12):2698-704. doi: 10.1016/j.ejca.2013.04.012. Epub 2013 May 15.


Fibrolamellar hepatocellular carcinoma in children and adolescents.

Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC.

Cancer. 2003 Apr 15;97(8):2006-12. Review.


Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies.

Murawski M, Weeda VB, Maibach R, Morland B, Roebuck DJ, Zimmerman A, Casanova M, Perilongo G, Laithier V, Kebudi R, Scopinaro MJ, Shun A, Brichard B, de Camargo B, Childs M, Aronson DC, Czauderna P.

J Clin Oncol. 2016 Apr 1;34(10):1050-6. doi: 10.1200/JCO.2014.60.2250. Epub 2016 Jan 25.


Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.

Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G.

J Clin Oncol. 2010 May 20;28(15):2584-90. doi: 10.1200/JCO.2009.22.4857. Epub 2010 Apr 20.


[Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].

Häberle B, Bode U, von Schweinitz D.

Klin Padiatr. 2003 May-Jun;215(3):159-65. German.


Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma.

El-Gazzaz G, Wong W, El-Hadary MK, Gunson BK, Mirza DF, Mayer AD, Buckels JA, McMaster P.

Transpl Int. 2000;13 Suppl 1:S406-9.


Rationale and results of the International Society of Pediatric Oncology (SIOP) Italian pilot study on childhood hepatoma: surgical resection d'emblée or after primary chemotherapy?

Guglielmi M, Perilongo G, Cecchetto G, Rondelli R, Lanino E, Siracusa F.

J Surg Oncol Suppl. 1993;3:122-6. Review. No abstract available.


Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: a SIOP pilot study.

Ninane J, Perilongo G, Stalens JP, Guglielmi M, Otte JB, Mancini A.

Med Pediatr Oncol. 1991;19(3):199-203.


Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.

Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC.

J Clin Oncol. 2002 Jun 15;20(12):2789-97.


Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection.

Malouf GG, Brugières L, Le Deley MC, Faivre S, Fabre M, Paradis V, Aerts I, Le Tourneau C, Dreyer C, Branchereau S, Belghiti J, Raymond E.

Cancer. 2012 Oct 15;118(20):4981-90. doi: 10.1002/cncr.27520. Epub 2012 Mar 13.


A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.

Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T.

Eur J Cancer Care (Engl). 2009 Sep;18(5):492-9. doi: 10.1111/j.1365-2354.2008.00984.x.


Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.

Schnater JM, Aronson DC, Plaschkes J, Perilongo G, Brown J, Otte JB, Brugieres L, Czauderna P, MacKinlay G, Vos A.

Cancer. 2002 Feb 15;94(4):1111-20.


Outcome of patients with fibrolamellar hepatocellular carcinoma.

Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D'Angelica M, Abou-Alfa G, Blumgart LH, DeMatteo RP.

Cancer. 2006 Mar 15;106(6):1331-8.


Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors.

Casanova M, Massimino M, Ferrari A, Spreafico F, Piva L, Coppa J, Luksch R, Cefalo G, Terenziani M, Polastri D, Bellani FF, Mazzaferro V.

Pediatr Hematol Oncol. 2005 Apr-May;22(3):189-98.


Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: a case-control study.

Chau GY, Lui WY, Tsay SH, Chao Y, King KL, Wu CW.

Ann Surg Oncol. 2006 Oct;13(10):1329-37. Epub 2006 Aug 5.


Salvage surgery following downstaging of unresectable hepatocellular carcinoma.

Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW.

Ann Surg. 2004 Aug;240(2):299-305.

Supplemental Content

Support Center